WO2020012036A1 - Variants d'anticorps cd38 et leurs utilisations - Google Patents

Variants d'anticorps cd38 et leurs utilisations Download PDF

Info

Publication number
WO2020012036A1
WO2020012036A1 PCT/EP2019/069028 EP2019069028W WO2020012036A1 WO 2020012036 A1 WO2020012036 A1 WO 2020012036A1 EP 2019069028 W EP2019069028 W EP 2019069028W WO 2020012036 A1 WO2020012036 A1 WO 2020012036A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antibody variant
seq
region
cancer
Prior art date
Application number
PCT/EP2019/069028
Other languages
English (en)
Inventor
Bart E C G DE GOEIJ
Grietje ANDRINGA
Frank Beurskens
Janine Schuurman
David Satijn
Tahamtan Ahmadi
Original Assignee
Genmab A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2021500814A priority Critical patent/JP2021524276A/ja
Priority to SG11202012993SA priority patent/SG11202012993SA/en
Priority to MX2020013631A priority patent/MX2020013631A/es
Priority to CR20210081A priority patent/CR20210081A/es
Priority to BR112020026432-6A priority patent/BR112020026432A2/pt
Priority to CN201980047066.7A priority patent/CN112513082A/zh
Priority to EA202190268A priority patent/EA202190268A1/ru
Priority to CA3106146A priority patent/CA3106146A1/fr
Application filed by Genmab A/S filed Critical Genmab A/S
Priority to AU2019300223A priority patent/AU2019300223A1/en
Priority to KR1020217003848A priority patent/KR20210031932A/ko
Priority to PE2021000038A priority patent/PE20211858A1/es
Priority to EP19742548.1A priority patent/EP3820900A1/fr
Publication of WO2020012036A1 publication Critical patent/WO2020012036A1/fr
Priority to IL279937A priority patent/IL279937A/en
Priority to PH12021550054A priority patent/PH12021550054A1/en
Priority to DO2021000006A priority patent/DOP2021000006A/es
Priority to CONC2021/0001544A priority patent/CO2021001544A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des variants d'anticorps comprenant une ou plusieurs mutations dans la région Fc, en particulier des anticorps anti-CD38 comprenant une mutation dans un ou plusieurs résidus d'acides aminés correspondant à E430, E345 et S440 dans une chaîne lourde IgG1 humaine, les résidus d'acides aminés étant numérotés selon l'indice EU.
PCT/EP2019/069028 2018-07-13 2019-07-15 Variants d'anticorps cd38 et leurs utilisations WO2020012036A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2019300223A AU2019300223A1 (en) 2018-07-13 2019-07-15 Variants of CD38 antibody and uses thereof
SG11202012993SA SG11202012993SA (en) 2018-07-13 2019-07-15 Variants of cd38 antibody and uses thereof
KR1020217003848A KR20210031932A (ko) 2018-07-13 2019-07-15 Cd38 항체의 변이체 및 그의 용도
BR112020026432-6A BR112020026432A2 (pt) 2018-07-13 2019-07-15 variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso
CN201980047066.7A CN112513082A (zh) 2018-07-13 2019-07-15 Cd38抗体变体及其用途
EA202190268A EA202190268A1 (ru) 2019-05-16 2019-07-15 Варианты антитела против cd38 и их применение
CA3106146A CA3106146A1 (fr) 2018-07-13 2019-07-15 Variants d'anticorps cd38 et leurs utilisations
JP2021500814A JP2021524276A (ja) 2018-07-13 2019-07-15 Ｃｄ３８抗体のバリアントおよびその使用
MX2020013631A MX2020013631A (es) 2018-07-13 2019-07-15 Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas.
CR20210081A CR20210081A (es) 2018-07-13 2019-07-15 Variantes de anticuerpos anti-cd38 y sus usos.
PE2021000038A PE20211858A1 (es) 2018-07-13 2019-07-15 Variantes de anticuerpos anti-cd38 y sus usos
EP19742548.1A EP3820900A1 (fr) 2018-07-13 2019-07-15 Variants d'anticorps cd38 et leurs utilisations
IL279937A IL279937A (en) 2018-07-13 2021-01-04 CD38 antibody variants and their uses
PH12021550054A PH12021550054A1 (en) 2018-07-13 2021-01-08 Variants of cd38 antibody and uses thereof
DO2021000006A DOP2021000006A (es) 2018-07-13 2021-01-11 Variantes de anticuerpos anti-cd38 y sus usos
CONC2021/0001544A CO2021001544A2 (es) 2018-07-13 2021-02-10 Variantes de anticuerpos anti-cd38 y sus usos

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862697730P 2018-07-13 2018-07-13
US62/697,730 2018-07-13
US201962848874P 2019-05-16 2019-05-16
US62/848,874 2019-05-16

Publications (1)

Publication Number Publication Date
WO2020012036A1 true WO2020012036A1 (fr) 2020-01-16

Family

ID=67396922

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/069028 WO2020012036A1 (fr) 2018-07-13 2019-07-15 Variants d'anticorps cd38 et leurs utilisations

Country Status (21)

Country Link
US (2) US20200017600A1 (fr)
EP (1) EP3820900A1 (fr)
JP (1) JP2021524276A (fr)
KR (1) KR20210031932A (fr)
CN (1) CN112513082A (fr)
AU (1) AU2019300223A1 (fr)
BR (1) BR112020026432A2 (fr)
CA (1) CA3106146A1 (fr)
CL (1) CL2021000066A1 (fr)
CO (1) CO2021001544A2 (fr)
CR (1) CR20210081A (fr)
DO (1) DOP2021000006A (fr)
EC (1) ECSP21010092A (fr)
IL (1) IL279937A (fr)
MA (1) MA53122A (fr)
MX (1) MX2020013631A (fr)
PE (1) PE20211858A1 (fr)
PH (1) PH12021550054A1 (fr)
SG (1) SG11202012993SA (fr)
TW (1) TW202019518A (fr)
WO (1) WO2020012036A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175920A1 (fr) 2021-02-22 2022-08-25 Janssen Biotech, Inc. Polythérapies à anticorps anti-cd38 et inhibiteurs des récepteurs parp ou de l'adénosine
WO2023079494A1 (fr) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Réduction de corticostéroïde dans un traitement avec des anticorps anti-cd38

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
WO2023044346A2 (fr) 2021-09-14 2023-03-23 Ausper Biopharma Co., Ltd. Vaccins pour la prévention et le traitement de coronavirus
AU2022350815A1 (en) * 2021-09-23 2024-05-02 Sound Biopharmaceuticals Co. Ltd. Cd38 monoclonal antibody and application thereof
CN114409788B (zh) * 2022-03-04 2022-10-04 四川大学华西医院 抗cd38的抗体及其应用

Citations (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5697902A (en) 1985-07-05 1997-12-16 Immunomedics, Inc. Method for imaging and treating organs and tissues
WO1998050431A2 (fr) 1997-05-02 1998-11-12 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
US5973972A (en) 1995-11-03 1999-10-26 Samsung Electronics, Co., Ltd. Precharge system for a semiconductor memory device
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
WO2000046147A2 (fr) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2000070087A1 (fr) 1999-05-14 2000-11-23 Copernicus Therapeutics, Inc. Dispositif automatise de compactage d'acide nucleique
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
WO2002020039A2 (fr) 2000-09-04 2002-03-14 Horst Lindhofer Utilisation d'anticorps trifonctionnels bispecifiques et trispecifiques dans le traitement d'ascites malignes
WO2002030954A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
WO2002031140A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
WO2006099875A1 (fr) 2005-03-23 2006-09-28 Genmab A/S Anticorps diriges contre cd38 pour le traitement du myelome multiple
WO2007042309A2 (fr) 2005-10-12 2007-04-19 Morphosys Ag Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
WO2007059782A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
US7262028B2 (en) 2002-07-18 2007-08-28 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2007110205A2 (fr) 2006-03-24 2007-10-04 Merck Patent Gmbh Domaines de proteine heterodimerique d'ingenierie
EP1870459A1 (fr) 2005-03-31 2007-12-26 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d'un ensemble
WO2008003116A2 (fr) 2006-07-05 2008-01-10 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Procédé de fabrication d'immunoglobulines
WO2008037257A2 (fr) 2006-09-26 2008-04-03 Genmab A/S Traitement combiné de tumeurs exprimant la cd38
WO2008047242A2 (fr) 2006-10-19 2008-04-24 Sanofi-Aventis Nouveaux anticorps anti-cd38 pour le traitement du cancer
WO2008157379A2 (fr) 2007-06-21 2008-12-24 Macrogenics, Inc. Di-anticorps covalents et leurs utilisations
WO2009089004A1 (fr) 2008-01-07 2009-07-16 Amgen Inc. Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2010080538A1 (fr) 2008-12-19 2010-07-15 Macrogenics, Inc. Diabodies covalents et leurs utilisations
US20100226923A1 (en) 2007-10-15 2010-09-09 Sanofi-Aventis Antibodies that bind il-4 and/or il-13 and their uses
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
WO2010151792A1 (fr) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
WO2011069104A2 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Anticorps plurispécifiques, analogues d'anticorps, compositions et procédés
WO2011117329A1 (fr) 2010-03-26 2011-09-29 F. Hoffmann-La Roche Ag Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
WO2011131746A2 (fr) 2010-04-20 2011-10-27 Genmab A/S Protéines contenant des anticorps fc hétérodimères et leurs procédés de production
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
EP2391343A2 (fr) 2009-01-29 2011-12-07 Alnylam Pharmaceuticals Inc. Préparation lipidique améliorée
WO2011154453A1 (fr) 2010-06-09 2011-12-15 Genmab A/S Anticorps dirigés contre le cd38 humain
WO2012023053A2 (fr) 2010-08-16 2012-02-23 Novimmune S.A. Procédé de production d'anticorps multispécifiques et multivalents
WO2012025530A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure
WO2012025525A1 (fr) 2010-08-24 2012-03-01 Roche Glycart Ag Anticorps bispécifiques activables
WO2012058768A1 (fr) 2010-11-05 2012-05-10 Zymeworks Inc. Conception d'anticorps hétérodimérique stable ayant des mutations dans le domaine fc
WO2012092612A1 (fr) 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps anti-cd38
WO2013004841A1 (fr) * 2011-07-06 2013-01-10 Genmab A/S Modulation de la cytotoxicité dépendante du complément par des modifications de l'extrémité c-terminale des chaînes lourdes d'anticorps
WO2013004842A2 (fr) 2011-07-06 2013-01-10 Genmab A/S Variants d'anticorps et leurs utilisations
WO2013157953A1 (fr) 2012-04-20 2013-10-24 Merus B.V. Procédés et moyens de production de molécules de type ig
WO2014031646A2 (fr) 2012-08-20 2014-02-27 Gliknik Inc. Molécules présentant une activité de liaison à l'antigène et de liaison aux récepteurs polyvalents fc gamma
WO2014108198A1 (fr) 2013-01-10 2014-07-17 Genmab B.V. Variantes de la région fc d'igg1 humaine et leurs utilisations
WO2014152774A1 (fr) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Procédés et compositions de délivrance d'anticorps codés par arnm
US20140348839A1 (en) 2011-12-20 2014-11-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
EP2869845A1 (fr) * 2012-07-06 2015-05-13 Genmab B.V. Protéine dimérique ayant des mutations triples
WO2015158867A1 (fr) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Protéines fc multimères
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
EP2972360A1 (fr) 2013-03-15 2016-01-20 Shire Human Genetic Therapies, Inc. Stimulation synergique de l'administration d'acides nucléiques par le biais de formulations mélangées
US20160185840A1 (en) 2007-01-09 2016-06-30 Curevac Ag Rna-coded antibody
WO2016189532A1 (fr) * 2015-05-26 2016-12-01 Ramot At Tel-Aviv University Ltd. Particules lipidiques ciblées pour l'administration systémique de molécules d'acide nucléique vers des leucocytes
WO2016210223A1 (fr) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
WO2018006052A1 (fr) 2016-06-30 2018-01-04 Protiva Biotherapeutics, Inc. Compositions et procédés pour l'administration d'arn messager
WO2018031258A1 (fr) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
US20180170866A1 (en) 2016-12-21 2018-06-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
WO2018114877A1 (fr) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Glyco-ingénierie in vitro d'anticorps
WO2018114878A1 (fr) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Réutilisation d'enzymes dans la glycoingénierie in vitro d'anticorps
WO2018114879A1 (fr) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Procédé de glycoingénierie in vitro d'anticorps
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10195156B2 (en) 2015-12-22 2019-02-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
CN113527512A (zh) * 2013-07-31 2021-10-22 美国安进公司 生长分化因子15(gdf-15)构建体
CN109476737A (zh) * 2015-12-01 2019-03-15 根马布有限公司 抗dr5抗体及其使用方法

Patent Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5697902A (en) 1985-07-05 1997-12-16 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
USRE35500E (en) 1989-08-09 1997-05-06 Aberlyn Capital Management Limited Partnership Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5973972A (en) 1995-11-03 1999-10-26 Samsung Electronics, Co., Ltd. Precharge system for a semiconductor memory device
WO1998050431A2 (fr) 1997-05-02 1998-11-12 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO2000046147A2 (fr) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
EP1176195A1 (fr) 1999-04-09 2002-01-30 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2000070087A1 (fr) 1999-05-14 2000-11-23 Copernicus Therapeutics, Inc. Dispositif automatise de compactage d'acide nucleique
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
WO2002020039A2 (fr) 2000-09-04 2002-03-14 Horst Lindhofer Utilisation d'anticorps trifonctionnels bispecifiques et trispecifiques dans le traitement d'ascites malignes
WO2002031140A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
WO2002030954A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
US7262028B2 (en) 2002-07-18 2007-08-28 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2006099875A1 (fr) 2005-03-23 2006-09-28 Genmab A/S Anticorps diriges contre cd38 pour le traitement du myelome multiple
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
EP1870459A1 (fr) 2005-03-31 2007-12-26 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d'un ensemble
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007042309A2 (fr) 2005-10-12 2007-04-19 Morphosys Ag Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
WO2007059782A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
WO2007110205A2 (fr) 2006-03-24 2007-10-04 Merck Patent Gmbh Domaines de proteine heterodimerique d'ingenierie
WO2008003116A2 (fr) 2006-07-05 2008-01-10 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Procédé de fabrication d'immunoglobulines
WO2008037257A2 (fr) 2006-09-26 2008-04-03 Genmab A/S Traitement combiné de tumeurs exprimant la cd38
WO2008047242A2 (fr) 2006-10-19 2008-04-24 Sanofi-Aventis Nouveaux anticorps anti-cd38 pour le traitement du cancer
EP3118224A1 (fr) 2007-01-09 2017-01-18 CureVac AG Anticorps codés arn
US20160185840A1 (en) 2007-01-09 2016-06-30 Curevac Ag Rna-coded antibody
WO2008157379A2 (fr) 2007-06-21 2008-12-24 Macrogenics, Inc. Di-anticorps covalents et leurs utilisations
US20100226923A1 (en) 2007-10-15 2010-09-09 Sanofi-Aventis Antibodies that bind il-4 and/or il-13 and their uses
WO2009089004A1 (fr) 2008-01-07 2009-07-16 Amgen Inc. Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
WO2010080538A1 (fr) 2008-12-19 2010-07-15 Macrogenics, Inc. Diabodies covalents et leurs utilisations
EP2391343A2 (fr) 2009-01-29 2011-12-07 Alnylam Pharmaceuticals Inc. Préparation lipidique améliorée
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
WO2010151792A1 (fr) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
WO2011069104A2 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Anticorps plurispécifiques, analogues d'anticorps, compositions et procédés
WO2011117329A1 (fr) 2010-03-26 2011-09-29 F. Hoffmann-La Roche Ag Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
WO2011131746A2 (fr) 2010-04-20 2011-10-27 Genmab A/S Protéines contenant des anticorps fc hétérodimères et leurs procédés de production
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
WO2011154453A1 (fr) 2010-06-09 2011-12-15 Genmab A/S Anticorps dirigés contre le cd38 humain
WO2012023053A2 (fr) 2010-08-16 2012-02-23 Novimmune S.A. Procédé de production d'anticorps multispécifiques et multivalents
WO2012025530A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure
WO2012025525A1 (fr) 2010-08-24 2012-03-01 Roche Glycart Ag Anticorps bispécifiques activables
WO2012058768A1 (fr) 2010-11-05 2012-05-10 Zymeworks Inc. Conception d'anticorps hétérodimérique stable ayant des mutations dans le domaine fc
WO2012092612A1 (fr) 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps anti-cd38
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
WO2013004842A2 (fr) 2011-07-06 2013-01-10 Genmab A/S Variants d'anticorps et leurs utilisations
WO2013004841A1 (fr) * 2011-07-06 2013-01-10 Genmab A/S Modulation de la cytotoxicité dépendante du complément par des modifications de l'extrémité c-terminale des chaînes lourdes d'anticorps
US20140348839A1 (en) 2011-12-20 2014-11-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
WO2013157953A1 (fr) 2012-04-20 2013-10-24 Merus B.V. Procédés et moyens de production de molécules de type ig
EP2869845A1 (fr) * 2012-07-06 2015-05-13 Genmab B.V. Protéine dimérique ayant des mutations triples
WO2014031646A2 (fr) 2012-08-20 2014-02-27 Gliknik Inc. Molécules présentant une activité de liaison à l'antigène et de liaison aux récepteurs polyvalents fc gamma
WO2014108198A1 (fr) 2013-01-10 2014-07-17 Genmab B.V. Variantes de la région fc d'igg1 humaine et leurs utilisations
WO2014152774A1 (fr) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Procédés et compositions de délivrance d'anticorps codés par arnm
EP2972360A1 (fr) 2013-03-15 2016-01-20 Shire Human Genetic Therapies, Inc. Stimulation synergique de l'administration d'acides nucléiques par le biais de formulations mélangées
WO2015158867A1 (fr) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Protéines fc multimères
WO2016189532A1 (fr) * 2015-05-26 2016-12-01 Ramot At Tel-Aviv University Ltd. Particules lipidiques ciblées pour l'administration systémique de molécules d'acide nucléique vers des leucocytes
WO2016210223A1 (fr) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
US10195156B2 (en) 2015-12-22 2019-02-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018006052A1 (fr) 2016-06-30 2018-01-04 Protiva Biotherapeutics, Inc. Compositions et procédés pour l'administration d'arn messager
WO2018031258A1 (fr) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
US20180170866A1 (en) 2016-12-21 2018-06-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
WO2018114877A1 (fr) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Glyco-ingénierie in vitro d'anticorps
WO2018114878A1 (fr) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Réutilisation d'enzymes dans la glycoingénierie in vitro d'anticorps
WO2018114879A1 (fr) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Procédé de glycoingénierie in vitro d'anticorps

Non-Patent Citations (95)

* Cited by examiner, † Cited by third party
Title
"UniProt", Database accession no. P01861
"UniProtKB", Database accession no. P28907
ANTONELLI, A.P. FALLAHI ET AL.: "Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease", CLIN EXP IMMUNOL, vol. 126, no. 3, 2001, pages 426 - 431, XP055280570, DOI: 10.1046/j.1365-2249.2001.01683.x
AUSIELLO, C. M.F. URBANI ET AL.: "Functional topography of discrete domains of human CD38", TISSUE ANTIGENS, vol. 56, no. 6, 2000, pages 539 - 547, XP002395101, DOI: 10.1034/j.1399-0039.2000.560608.x
BARBAS ET AL., J MOL BIOL., vol. 230, no. 3, 5 April 1993 (1993-04-05), pages 812 - 23
BEBBINGTON, BIOTECHNOLOGY, vol. 10, 1992, pages 169 - 175
BENVENISTYRESHEF, PNAS USA, vol. 83, 1986, pages 9551 55
BEURSKENS ET AL., J IMMUNOL, vol. 188, no. 7, 1 April 2012 (2012-04-01), pages 3532 - 3541
BREZSKI, R. J.G. GEORGIOU: "Immunoglobulin isotype knowledge and application to Fc engineering", CURR OPIN IMMUNOL, vol. 40, 2016, pages 62 - 69, XP029551348, DOI: 10.1016/j.coi.2016.03.002
C. A. DIEBOLDER ET AL: "Complement Is Activated by IgG Hexamers Assembled at the Cell Surface", SCIENCE, NIH AUTHOR MANUSCRIPT, vol. 343, no. 6176, 14 March 2014 (2014-03-14), US, pages 1260 - 1263, XP055268754, ISSN: 0036-8075, DOI: 10.1126/science.1248943 *
CHATTERJEE, S.A. DAENTHANASANMAK ET AL.: "CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response", CELL METAB, vol. 27, no. 1, 2018, pages 85 - 100
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 917
COMB, CHEM HIGH THROUGHPUT SCREEN, vol. 6, no. 4, June 2003 (2003-06-01), pages 367 - 79
CORAROPEARSON, SOMATIC CELL GENETICS, vol. 7, 1981, pages 603
COTNER, T.M. HEMLER ET AL.: "Human T cell proteins recognized by rabbit heteroantisera and monoclonal antibodies", INT J IMMUNOPHARMACOL, vol. 3, no. 3, 1981, pages 255 - 268, XP025484032, DOI: 10.1016/0192-0561(81)90019-9
COX ET AL., NATURE BIOTECHNOLOGY, vol. 12, 2006, pages 1591 - 1597
DALL'ACQUA, W. F.K. E. COOK ET AL.: "Modulation of the effector functions of a human IgG1 through engineering of its hinge region", J IMMUNOL, vol. 177, no. 2, 2006, pages 1129 - 1138, XP002497452
DAMLE, R. E. A.: "Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia", BLOOD, vol. 94, no. 6, 1999, pages 1840 - 1847, XP002989134
DAVIES ET AL., BIOTECHNOL BIOENG, vol. 74, 2001, pages 288 - 294
DE LANGE, EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, vol. 6, no. 1, September 1989 (1989-09-01), pages 7 - 17
DE WEERS, M.Y. T. TAI ET AL.: "Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors", J IMMUNOL, vol. 186, no. 3, 2011, pages 1840 - 1848, XP055210884, DOI: 10.4049/jimmunol.1003032
DECKERT, J.M. C. WETZEL ET AL.: "SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies", CLIN CANCER RES, vol. 20, no. 17, 2014, pages 4574 - 4583, XP055239997, DOI: 10.1158/1078-0432.CCR-14-0695
DESHPANDE, D. A.T. A. WHITE ET AL.: "Altered airway responsiveness in CD38-deficient mice", AM J RESPIR CELL MOL BIOL, vol. 32, no. 2, 2005, pages 149 - 156, XP055078284, DOI: 10.1165/rcmb.2004-0243OC
DESJARLAIS, J. R.G. A. LAZAR: "Modulation of antibody effector function", EXP CELL RES, vol. 317, no. 9, 2011, pages 1278 - 1285
DIMASI, N. ET AL., J MOL BIOL, vol. 393, no. 3, 2009, pages 672 - 92
DING ET AL., HUMAN IMMUNOLOGY, vol. 76, 2015, pages 615 - 621
E. MEYERSW. MILLER, COMPUT. APPL. BIOSCI, vol. 4, 1988, pages 11 - 17
EDELMAN ET AL., PROC NATL ACAD SCI USA., vol. 63, no. l, May 1969 (1969-05-01), pages 78 - 85
EHRENMANN F.KAAS Q.LEFRANC M.-P., NUCLEIC ACIDS RES., vol. 38, 2010, pages 301 - 307
EISSLER, N.S. FILOSTO ET AL.: "A best in class anti-CD38 antibody with antitumor and immune-modulatory properties", AACR ANNUAL MEETING 2018, 2018
FENG X.ZHANG L. ET AL.: "Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma", CLIN CANCER RES, vol. 23, 2017, pages 4290 - 4300, XP055497699, DOI: 10.1158/1078-0432.CCR-16-3192
GRANT ET AL., METHODS IN ENZYMOL, vol. 153, 1987, pages 516 544
HAMERS-CASTERMAN, NATURE, vol. 363, 1993, pages 446
HAMILTON ET AL., SCIENCE, vol. 301, 2003, pages 1244 - 1246
HO, H. N.L. E. HULTIN ET AL.: "Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens", J IMMUNOL, vol. 150, no. 7, 1993, pages 3070 - 3079
IMCLONEELI LILLY, SHEN, J. ET AL., J IMMUNOL METHODS, vol. 318, no. 1-2, 2007, pages 65 - 74
KABAT ET AL.: "Sequences of proteins of immunological interest", 1991, NIH
KANEKO, E.R. NIWA: "Optimizing therapeutic antibody function: progress with Fc domain engineering", BIODRUGS, vol. 25, no. 1, 2011, pages 1 - 11, XP002658156
KARAKASHEVA T. A.WALDRON T. J. ET AL.: "CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer", CANCER RES, vol. 75, no. 19, 2015, pages 4074 - 85, XP055496986, DOI: 10.1158/0008-5472.CAN-14-3639
KESTENS, L., G. VANHAM ET AL.: "Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection", AIDS, vol. 6, no. 8, 1992, pages 793 - 797
KEYHANI, A.Y. O. HUH ET AL.: "Increased CD38 expression is associated with favorable prognosis in adult acute leukemia", LEUK RES, vol. 24, no. 2, 2000, pages 153 - 159
KONOPLEV, S.L. J. MEDEIROS ET AL.: "Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia", AM J CLIN PATHOL, vol. 124, no. 3, 2005, pages 414 - 420
KREJCIK, J.K. A. FRERICHS ET AL.: "Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab", CLIN CANCER RES, vol. 23, no. 24, 2017, pages 7498 - 7511
KREJCIK, J.T. CASNEUF ET AL.: "Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma", BLOOD, vol. 128, 2016, pages 384 - 394, XP055460007, doi:10.1182/blood-2015-12-687749
LAMMERTS VAN BUEREN, J.D. JAKOBS ET AL.: "Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79", BLOOD, vol. 124, no. 21, 2014, pages 3474
LANDE, R.F. URBANI ET AL.: "CD38 ligation plays a direct role in the induction of IL-lbeta, IL-6, and IL-10 secretion in resting human monocytes", CELL IMMUNOL, vol. 220, no. 1, 2002, pages 30 - 38
LEE, H. C.R. AARHUS: "Wide distribution of an enzyme that catalyzes the hydrolysis of cyclic ADP-ribose", BIOCHIM BIOPHYS ACTA, vol. 1164, no. 1, 1993, pages 68 - 74, XP023469413, DOI: 10.1016/0167-4838(93)90113-6
LEFRANC MP., NUCLEIC ACIDS RESEARCH, vol. 27, 1999, pages 209 - 212
LIN, P.R. OWENS ET AL.: "Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma", AM J CLIN PATHOL, vol. 121, no. 4, 2004, pages 482 - 488
LINDHOFER ET AL.: "Pharma/Fresenius Biotech", J IMMUNOL, vol. 155, 1995, pages 219
LIU ET AL., J PHARM SCI, vol. 97, 2008, pages 2426
MALAVASI, F.A. FUNARO ET AL.: "Human CD38: a glycoprotein in search of a function", IMMUNOL TODAY, vol. 15, no. 3, 1994, pages 95 - 97, XP024347473, DOI: 10.1016/0167-5699(94)90148-1
MALLONE, R.P. C. PERIN: "Anti-CD38 autoantibodies in type? diabetes", DIABETES METAB RES REV, vol. 22, no. 4, 2006, pages 284 - 294
MARINOV, J.K. KOUBEK ET AL.: "Immunophenotypic Significance of the Lymphoid Cd38 Antigen in Myeloid Blood Malignancies", NEOPLASMA, vol. 40, no. 6, 1993, pages 355 - 358
MOORE, G. L.H. CHEN ET AL.: "Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions", MABS, vol. 2, no. 2, 2010, pages 181 - 189, XP009143498, DOI: 10.4161/mabs.2.2.11158
MORANDI F.HORENSTEIN A. L. ET AL.: "CD56brightCD16 NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation", J IMMUNOL, vol. 195, 2015, pages 965 - 972
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
NIJHOF ET AL., BLOOD, vol. 128, no. 7, 2016, pages 959 - 970
NIJHOF ET AL., SUPPLEMENTAL METHODS, 2016
OKAZAKI ET AL., JMB, vol. 336, 2004, pages 1239 - 49
OVERDIJK M.B. ET AL., MABS, vol. 7, no. 2, pages 311 - 320
PARRY-JONES, N.E. MATUTES ET AL.: "Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH", BR J HAEMATOL, vol. 137, no. 2, 2007, pages 117 - 124
PATEL A ET AL., CELL REPORTS, vol. 25, 2018, pages 1982 - 1993
PATTON, D. T.WILSON M. D. ET AL.: "The PI3K p110ó Regulates Expression of CD38 on Regulatory T cells", PLOS ONE, vol. 6, no. 3, 2011, pages 1 - 8
PERFETTI, V.V. BELLOTTI ET AL.: "AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies", LAB INVEST, vol. 71, no. 6, 1994, pages 853 - 861
POTGIETER ET AL., J. BIOTECHNOLOGY, vol. 139, 2009, pages 318 - 325
RAAB, M. S.H. GOLDSCHMIDT ET AL.: "A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM", J CLIN ONCOL, vol. 33, 2015, pages A8574
RAJKUMAR S VINCENT: "Daratumumab in multiple myeloma", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 387, no. 10027, 7 January 2016 (2016-01-07), pages 1490 - 1492, XP029496409, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(15)01226-X *
RAJKUMAR, HAROUSSEAU ET AL.: "Blood", vol. 117, 2011, INTERNATIONAL MYELOMA WORKSHOP CONSENSUS PANEL, article "Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel", pages: 4691 - 4695
RAMASCHI, G.M. TORTI ET AL.: "Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane", BLOOD, vol. 87, no. 6, 1996, pages 2308 - 2313
REMINGTON: "he Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO.
ROEPCKE, S.N. PLOCK ET AL.: "Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial", PHARMACOL RES PERSPECT, vol. 6, no. 3, 2018, pages e00402
SCHAKOWSKI ET AL., MOL THER, vol. 3, 2001, pages 793 800
SCHLAKE ET AL., MOLECULAR THERAPY, vol. 27, April 2019 (2019-04-01)
SCHOOTEN, W. V.: "Multispecific antibodies targeting CD38 and PD-L1 show potent tumor cytotoxicity", AACR ANNUAL MEETING, 2018
SHIELDS ET AL., J BIOL CHEM, vol. 277, 2002, pages 26733 - 26740
SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, pages 26733 - 26740
SHINKAWA ET AL., J BIOL CHEM, vol. 278, 2003, pages 3466 - 3473
SONDERMANN, P.D. E. SZYMKOWSKI: "Harnessing Fc receptor biology in the design of therapeutic antibodies", CURR OPIN IMMUNOL, vol. 40, 2016, pages 78 - 87, XP029551351, DOI: 10.1016/j.coi.2016.03.005
SONG, A.K. MYOJO ET AL.: "Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates", ANTIVIRAL RES, vol. 111, 2014, pages 60 - 68, XP029089994, DOI: 10.1016/j.antiviral.2014.08.016
SUZUKI, R.J. SUZUMIYA ET AL.: "Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells", LEUKEMIA, vol. 18, no. 4, 2004, pages 763 - 770
SYKESJOHNSTON, NAT BIOTECH, vol. 17, 1997, pages 355 59
UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 1
VAN BIJ ET AL., JOURNAL OF HEPATOLOGY, vol. 53, no. 4, October 2010 (2010-10-01), pages 677 - 685
VAN DE DONK NIELS W C J ED - PISTOIA VITO: "Immunomodulatory effects of CD38-targeting antibodies", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 199, 24 April 2018 (2018-04-24), pages 16 - 22, XP085404553, ISSN: 0165-2478, DOI: 10.1016/J.IMLET.2018.04.005 *
VAN DE DONK, N. W., H. M. LOKHORST ET AL.: "How I treat plasma cell leukemia", BLOOD, vol. 120, no. 12, 2012, pages 2376 - 2389
VAN DE DONK, N. W., M. L. JANMAAT ET AL.: "Monoclonal antibodies targeting CD38 in hematological malignancies and beyond", IMMUNOL REV, vol. 270, no. 1, 2016, pages 95 - 112, XP055498302, DOI: 10.1111/imr.12389
VAN DE DONK: "Immunomodulatory effects of CD38 targeting antibodies", IMMUNOLOGY LETTERS, vol. 199, 2018, pages 16 - 22, XP085404553, DOI: 10.1016/j.imlet.2018.04.005
VAN HEEKESCHUSTER, J BIOL CHEM, vol. 264, 1989, pages 5503 5509
VINK ET AL., METHODS, vol. 65, no. 1, 2014, pages 5 - 10
WANG, L., H. WANG ET AL.: "CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type", ANN HEMATOL, vol. 94, no. 8, 2015, pages 1381 - 1388, XP035505635, DOI: 10.1007/s00277-015-2359-2
WANG, X.M. MATHIEU ET AL.: "IgG Fc engineering to modulate antibody effector functions", PROTEIN & CELL, vol. 9, no. 1, 2018, pages 63 - 73, XP055457296, DOI: 10.1007/s13238-017-0473-8
WIGLER ET AL., CELL, vol. 14, 1978, pages 725
ZHANG, D., A. A. ARMSTRONG ET AL.: "Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization", MABS, vol. 9, no. 7, 2017, pages 1129 - 1142, XP055414189, DOI: 10.1080/19420862.2017.1358838
ZOCCHI, E., L. FRANCO ET AL.: "A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes", BIOCHEM BIOPHYS RES COMMUN, vol. 196, no. 3, 1993, pages 1459 - 1465, XP024766867, DOI: 10.1006/bbrc.1993.2416

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175920A1 (fr) 2021-02-22 2022-08-25 Janssen Biotech, Inc. Polythérapies à anticorps anti-cd38 et inhibiteurs des récepteurs parp ou de l'adénosine
WO2023079494A1 (fr) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Réduction de corticostéroïde dans un traitement avec des anticorps anti-cd38

Also Published As

Publication number Publication date
AU2019300223A1 (en) 2021-01-07
KR20210031932A (ko) 2021-03-23
TW202019518A (zh) 2020-06-01
US20200017600A1 (en) 2020-01-16
DOP2021000006A (es) 2021-03-15
PE20211858A1 (es) 2021-09-21
ECSP21010092A (es) 2021-03-31
CA3106146A1 (fr) 2020-01-16
JP2021524276A (ja) 2021-09-13
SG11202012993SA (en) 2021-02-25
CN112513082A (zh) 2021-03-16
MA53122A (fr) 2021-05-19
BR112020026432A2 (pt) 2021-03-23
CL2021000066A1 (es) 2021-05-28
IL279937A (en) 2021-03-01
PH12021550054A1 (en) 2021-09-27
CO2021001544A2 (es) 2021-03-08
US20200165352A1 (en) 2020-05-28
MX2020013631A (es) 2021-03-25
CR20210081A (es) 2021-06-24
EP3820900A1 (fr) 2021-05-19

Similar Documents

Publication Publication Date Title
US20200165352A1 (en) Variants of cd38 antibody and uses thereof
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
WO2019223733A1 (fr) Anticorps anti-ox40 et procédés d'utilisation
CA3157042A1 (fr) Procedes de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des anticorps anti-tigit
WO2020012038A1 (fr) Thérapie à médiation par trogocytose utilisant des anticorps cd38
WO2021098769A1 (fr) Traitement du cancer à l'aide d'anticorps anti-ox40 et d'inhibiteurs de kinases multiples
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
US20230272105A1 (en) Formulations of cd38 antibodies and uses thereof
WO2022156726A1 (fr) Procédés de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1
WO2021098758A1 (fr) Procédés de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des anticorps anti-tim3
WO2021098774A1 (fr) Procédés de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des anticorps anti-pd1 ou anti-pdl1
WO2021098748A1 (fr) Procédés de traitement du cancer avec un anticorps anti-ox40 en combinaison avec des agents chimiothérapeutiques
CA3205839A1 (fr) Procedes de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1
WO2023218046A1 (fr) Agents de liaison capables de se lier à cd27 en polythérapie
EA040773B1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19742548

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020026432

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019300223

Country of ref document: AU

Date of ref document: 20190715

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3106146

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021500814

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217003848

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019742548

Country of ref document: EP

Effective date: 20210215

ENP Entry into the national phase

Ref document number: 112020026432

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201222